Mark Strobeck Insider Profile
4 Followers
Mark Strobeck, President & CEO, Director at Rockwell Med, holds 62.35K shares in Rockwell Med (Ticker: RMTI), holds 2.30K shares in Windtree Therapeutics (Ticker: WINT), holds 248.60K shares in Assertio Therapeutics (Ticker: ASRT).
Mark Strobeck's Trading History
| RMTIRockwell Med | Jul 06, 2026 | President & CEO, Director | Uninformative Buy | ― | $421.48K | |
| WINTWindtree Therapeutics | Aug 25, 2023 | Director | Uninformative Buy | ― | $27.60 | |
| ASRTAssertio Therapeutics | May 22, 2020 | ― | Uninformative Buy | ― | $5.84M | |
| ZCORZyla Life Sciences | May 21, 2020 | ― | Uninformative Sell | ― | $0.00 | |
| EGLTQEgalet Corp | Feb 04, 2019 | ― | Uninformative Sell | ― | $0.00 |
You May Also Like
Mark Strobeck insider profile FAQ
What stocks does Mark Strobeck hold?
Mark Strobeck holds: RMTI, ASRT, EGLTQ, WINT, ZCOR stocks.
What is Mark Strobeck's role in Rockwell Med?
Mark Strobeck's role in Rockwell Med is President & CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.
TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.
